Keywords: schering, ag, betaferon, cuts, risk, clinical, ms

Schering AG's Betaferon cuts risk of clinical MS

Article | 28 August 2006

Print This

German drugmaker Schering AG says that the results from a trial of Betaferon (interferon beta-1b), which is marketed as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in